Targeted Protein Degradation Market Report Scope & Overview:

The targeted protein degradation market size was valued at USD 540.23 million in 2024 and is expected to reach USD 2216.13 million by 2032, growing at a CAGR of 19.32% over the forecast period of 2025-2032. 

The global targeted protein degradation market is primarily boosted through its novel mechanism of action and Extreme demand by therapeutics, including PROTACs or Molecular Glues targeting degradation activity on previously un-druggable proteins- with each innovative stage, the chance within the target protein market increases. Moreover, the robust oncology pipeline propels growth higher as the targeted protein degradation market trends toward blood and cancer. These are trends reflecting advances in protein targeting and growth in hot therapeutic areas.

For instance, in March 2025, Arvinas expanded its oncology-focused TPD pipeline with new clinical trials for ARV-471 and ARV-766, highlighting growing targeted protein degradation market trends.

Key Targeted Protein Degradation Market Trends

• Expansion into traditionally “undruggable” targets, including transcription factors and disease-specific proteins in oncology, neurodegeneration, and autoimmune disorders.

• Increasing use of PROTACs, molecular glues, and optimized degrader designs for higher specificity and efficacy.

• Integration of AI, computational modeling, and high-throughput screening for faster, accurate drug discovery and candidate optimization.

• Focus on personalized medicine with TPD therapies tailored to patient-specific protein expression and genetic profiles.

• Collaborations between biotech, pharma, and CROs for co-development, licensing, and manufacturing scale-up globally.

• Development of novel delivery platforms, including nanoparticles, antibody conjugates, and oral degraders for patient-friendly administration.

• Growing clinical pipeline, biomarker-guided trials, and regulatory progress enhancing adoption and market confidence.

Targeted Protein Degradation Market Report Highlights

The U.S. targeted protein degradation market was valued at USD 212.57 million in 2024 and is expected to reach USD 861.45 million by 2032, growing at a CAGR of 19.14% over 2025-2032. The U.S. is dominating the targeted protein degradation market analysis as it holds the largest market share due to being a biotech innovation hub. Discover how industry leaders Arvinas, Kymera, and Nurix are advancing oncology-focused PROTACs and molecular glues by expanding both discovery and development pipelines while pushing candidates through clinical trials to commercialization. As the birthplace of so many innovations, this innovation-intensive environment is driving a growing global leadership available for the TPD market.

Targeted Protein Degradation Market Growth Drivers:

• Expansion into Non-Oncology Indications is Driving the Targeted Protein Degradation Market Growth

The expansion into non-oncology indications is driving the targeted protein degradation market share, as companies increasingly focus on neurological, immunological, and infectious diseases. Brain-penetrant PROTACs and molecular glues enable treatment of Alzheimer’s and Parkinson’s, while emerging modalities broaden therapeutic applications.

For instance, in June 2024, nearly 20% of global TPD candidates focus on neurological and immunological disorders, reflecting the Expansion into Non-Oncology Indications trend.

Targeted Protein Degradation Market Restraints:

• Complex Drug Design and Development is Hampering the Targeted Protein Degradation Market Growth

Development of PROTACs and molecular glues, which need complex drug design to restrain the targeted protein degradation market growth. Developing potent molecules required meticulous targeting of the E3 ligase, linker optimization, and structural stability. A dismal preclinical and early clinical failure rate drives up costs and risks, thus preventing the quick proliferation of the market, despite an attractive therapeutic appeal.

Targeted Protein Degradation Market Opportunities:

• Expansion Into Personalized Medicine Drives Future Growth Opportunities for the Targeted Protein Degradation Market

The potential is provided for customized treatments relevant to the proteomic and genetic backgrounds of individual patients through TPD-based therapeutics. Through targeting the proteins that truly drive disease, TPD can offer highly selective interventions, cut off-target damage, and deliver better treatments. These individualised strategies could facilitate precision medicine in cancer, neurodegenerative, and autoimmune diseases, and lead to improved patient response and safety.

For instance, in October 2024, over 160 TPD candidates are in clinical development, with 40+ in Phase II/III trials, reflecting rapid adoption and regulatory progress.

Key Targeted Protein Degradation Market Segment Analysis

• By therapeutic area, oncology held the largest share of around 61.38%in 2024, and the neurological disorders segment is expected to register the highest growth with a CAGR of 20.87%.

• By application, the therapy development segment dominated the market with approximately 57.57% share in 2024, while drug discovery is expected to register the highest growth with a CAGR of 19.75%.

• By type, PROTAC accounted for the leading share of nearly 48.98% in 2024, while molecular glues are expected to register the highest growth with a CAGR of 19.98%.

• By end user, the pharmaceutical & biotechnology companies segment led the market with about 40.80% share in 2024, while the hospital & clinical laboratories segment is forecasted to grow the fastest at a CAGR of 20.30%.

By Therapeutic Area, Oncology Leads the Market, While Neurological Disorders Register Fastest Growth

The oncology segment accounted for the highest revenue share of approximately 61.38% in 2024, driven by the completely new mechanisms of action offered by PROTACS and molecular glues, together with established, well-characterized clinical pipelines, billions in R&D investment, regulatory tailwinds, and broader strategic collaboration activity is driving significant growth of this nascent but rapidly maturing market for oncology-focused protein degraders. In comparison, the neurological disorders segment is anticipated to achieve the highest CAGR of nearly 20.87% during the 2025–2032 period, due to brain-penetrant PROTACS and increasing R&D investments, along with technological advancements in targeted protein degradation, are likely to continue to accelerate the current pace of innovation.

By Application, the Therapy Development Segment dominates, while the Drug Discovery Segment Shows Rapid Growth

The therapy development segment held the largest revenue share of approximately 57.57% in 2024, fueled by strong R&D pipelines and high clinical volumes. These include the emergence of new mechanisms, strategic partnerships, large amounts of money being invested into the field, regulatory incentives, and technological advancements. On the other hand, the drug discovery segment is predicted to grow at the strongest CAGR of approximately 19.75% during 2025–2032, with novel screening and detection methods, rising R&D investments in biotech pharma collaborations, and expanding non-cancerous pipelines.

By Type, PROTAC Segment Lead, While Molecular Glues Register Fastest Growth

The PROTAC segment accounted for the largest share of the Targeted Protein Degradation Market with about 48.98%, owing to improved efficacy, specificity, and catalytic proteolytic decay of proteins with lesser doses more safely. Their wide-ranging efficacy in oncology, neurological, and immunological diseases, and strong patent coverage. In addition, the Molecular Glues segment is slated to grow at the fastest rate with a CAGR of around 19.98% throughout the forecast period of 2025–2032, driven by their capability of stabilizing protein–ligase interactions and thereby degrading hitherto undruggable proteins. Rapid pipeline expansion of targets across various oncological, immunological, and neurological disorders is being propelled by rising R&D costs. 

By End User, Pharmaceutical & Biotechnology Companies Segment Lead, While the Hospital & Clinical Laboratories Segment Grows the Fastest

The Pharmaceutical & Biotechnology Companies segment held the largest revenue share of around 40.80% in the Targeted Protein Degradation Market in 2024, as a result of their deep R&D, almost unlimited funds, and some very shrewd alliances. Strong oncology and non-oncology pipelines, regulatory backing, technological innovations in PROTACs and molecular glues. On the flip side, the Hospital & Clinical Laboratories segment, however, is projected to register the highest CAGR of around 20.30% during the forecast period of 2025 - 2032, owing to a rise in the acceptance of TPD-based diagnosis and treatment services. The rapid expansion of the protein degradation global market is attributed to increasing clinical trial activity, a growing focus on advanced molecular testing, and personalized medicine.

Asia Pacific Targeted Protein Degradation Market Insights

Asia-Pacific is experiencing significant growth in the targeted protein degradation market, due to growing investments in biotechnology and pharmaceutical research & development, increasing prevalence of cancer and neurological diseases, and expandable medical infrastructure. For example, in countries including China, Japan, and South Korea, clinical trials capacity drives the market, with advanced PROTAC and molecular glue technologies widely accepted. In addition, favorable government regulations, lower manufacturing costs, and increasing collaboration of domestic players with global pharma are stimulating pipeline growth in the Asia-Pacific TPD market, thus making it a burgeoning region with promising prospects.

North America Targeted Protein Degradation Market Insights

North America accounted for the highest revenue share of approximately 46.72% in 2024 of the Targeted Protein Degradation Market, owing to its cluster of top biotech and pharma firms, mature clinical trial infrastructure, and numerous research partnerships. Moreover, government supportive funding, stringent IP regulations are likely to propel the research studies of PROTACs and Molecular glues, besides a shift in adoption of novel moieties, act as a catalyst for Proteolysis Targeting Chimera (PROTAC) Technology & Novel MOA-based products, fueling market growth. TPD innovation, development, and commercialization are most robust in North America for all these reasons.

Europe Targeted Protein Degradation Market Insights

The Europe region is projected to witness the fastest CAGR of 20.04% during the forecast period of 2025, owing to a mix of favorable regulations, rising R&D spend, and growing biotech communities. Germany, the U.K., and Switzerland are great examples where their respective governments offer support in the form of grants and incentives for innovative therapies, including PROTACs or molecular glues. There are also greater alliances in allying with European biotech companies by global pharmaceutical companies to fortify their clinical trial competencies and boost their pipelines. An increasing number of patients with oncology, neurological, and immunological disorders drives demand for personalized therapies. Moreover, Europe has a well-established research infrastructure, widespread acceptance of personalized medicines, and robustly protected intellectual property rights. Taken together, this places Europe as a fast-growing market for the TPD side of the opportunity space.

Latin America (LATAM) and Middle East & Africa (MEA) Targeted Protein Degradation Market Insights

The Latin America and Middle East & Africa targeted protein degradation market (TPD) is also growing due to rising healthcare expenditure, biotech alliances, and unmet medical needs. The areas are for clinical trial growth, local manufacturing, and enhanced access to next-gen protein degrader treatments.

Competitive Landscape for the Targeted Protein Degradation Market:

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The company offers a wide range of services, from biologics to gene therapies to soild doses, for pharmaceutical and biotechnology companies all over the globe.

• In February 2025, Catalent reported expanding its biologics and protein degrader manufacturing capabilities, supporting over 25 TPD programs globally, reflecting rising demand for PROTACs and molecular glue therapies.

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5,000 employees. It focuses on clean oral, sterile, and inhaled drug products, providing scalable solutions for the world's leading pharma companies with capacity, expertise, and data integrity focused on delivering compliant products to patients via the Wyeth model.

• As of January 2025, Recipharm announced a strategic partnership to provide clinical and commercial-scale production for 10+ TPD candidates, highlighting increased outsourcing of degrader development to CDMOs.

PCI Pharma Services is a fully integrated provider of out-sourced pharmaceutical services offering unparalleled expertise and experience in taking compounds from the earliest stages of development through to commercial launch, delivering speed to market and commercial success for its customers. It offers tailored, high-quality solutions in various dosage forms and markets.

• In March 2025, PCI Pharma Services expanded its specialty drug manufacturing and packaging lines to support early- and late-stage TPD therapeutics, enabling faster market entry and improved patient access.

Targeted Protein Degradation Market Key Players:

Some of the medical suction device market companies are:

• Arvinas, Inc. 

• Kymera Therapeutics, Inc.

• Nurix Therapeutics, Inc.

• Foghorn Therapeutics, Inc.

• Therapeutics, Inc. 

• Vividion Therapeutics, Inc.

• Bristol Myers Squibb (BMS)

• Novartis AG

• Pfizer Inc

• Amgen Inc.

• Astellas Pharma Inc.

• Merck & Co., Inc.

• Sanofi S.A.

• Roche Holding AG

• GlaxoSmithKline (GSK)

• Evotec SE

• Ascendis Pharma A/S 

• Monte Rosa Therapeutics

• Kyowa Kirin Co., Ltd.

• Arrowhead Pharmaceuticals, Inc